Education
About Us
Working with TipRanks
Follow Us
Avita Medical (RCEL)
NASDAQ:RCEL
RCEL Stock Chart & Stats
$3.99
-$5.13(-36.49%)
At close: 4:00 PM EST
$3.99
-$5.13(-36.49%)
Day’s Range― - ―
52-Week Range$3.60 - $14.16
Previous CloseN/A
Volume824.49K
Average Volume (3M)934.88K
Market Cap
$143.21M
Enterprise Value$168.38M
Total Cash (Recent Filing)$15.69M
Total Debt (Recent Filing)$44.59M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Nov 06, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding26,618,935
10 Day Avg. Volume141,848
30 Day Avg. Volume934,879
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)73.64
Price to Sales (P/S)5.16
P/FCF Ratio-5.69
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-3.77
Forecast
1Y Price Target
$7.00Price Target Upside75.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical Data And AdoptionThe recently presented clinical data highlight Avita's RECELL and Cohealyx offerings, encouraging commercial success.
Leadership And StrategyThe interim CEO is an industry veteran who will focus on a Board-backed plan centered on execution.
Product Portfolio And GrowthThere is a valuable portfolio of products with significant growth opportunity, including RECELL, Cohealyx, and PermeaDerm.
Bears Say
Cash Flow And ProfitabilityRCEL pushed back its timelines to free cash flow break-even and GAAP profitability, indicating further financial struggles.
Financial Performance And GuidanceRCEL has reduced guidance in 5 of the last 7 quarters and missed top-line in the past 3 quarters.
Reimbursement And DemandDemand for RECELL dropped approximately 20% as providers avoid any risk of not being paid.
Avita Medical News
RCEL FAQ
What was Avita Medical’s price range in the past 12 months?
Avita Medical lowest stock price was $3.60 and its highest was $14.16 in the past 12 months.
What is Avita Medical’s market cap?
Avita Medical’s market cap is $143.21M.
When is Avita Medical’s upcoming earnings report date?
Avita Medical’s upcoming earnings report date is Nov 06, 2025 which is in 18 days.
How were Avita Medical’s earnings last quarter?
Avita Medical released its earnings results on Aug 07, 2025. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.13.
Is Avita Medical overvalued?
According to Wall Street analysts Avita Medical’s price is currently Undervalued.
Does Avita Medical pay dividends?
Avita Medical does not currently pay dividends.
What is Avita Medical’s EPS estimate?
Avita Medical’s EPS estimate is -0.27.
How many shares outstanding does Avita Medical have?
Avita Medical has 26,618,935 shares outstanding.
What happened to Avita Medical’s price movement after its last earnings report?
Avita Medical reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -21.004%.
Which hedge fund is a major shareholder of Avita Medical?
Currently, no hedge funds are holding shares in RCEL
Avita Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (75.44% Upside)
$7.00 (75.44% Upside)
Blogger Sentiment
Bullish
RCEL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 14.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $113.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.89%
12-Months-Change
Fundamentals
Return on Equity
-935.73%
Trailing 12-Months
Asset Growth
-33.81%
Trailing 12-Months
Company Description
Avita Medical
Avita Medical (RCEL) is a biotechnology company focused on regenerative medicine, particularly in the field of wound care and skin regeneration. The company specializes in developing innovative products derived from human tissue, primarily its flagship product, the RECELL System, which enables the rapid preparation of a patient’s own skin cells for the treatment of burns, chronic wounds, and other skin defects. Avita Medical operates in the healthcare sector, aiming to improve outcomes for patients while reducing the costs associated with traditional skin grafting methods.
RCEL Company Deck
RCEL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including a 21% increase in commercial revenue and major clinical evidence supporting RECELL's effectiveness. Key challenges were noted in reimbursement delays impacting revenue and a lowered financial forecast. Despite the challenges, the company is optimistic about a recovery in the second half of the year and has implemented cost-saving measures.View all RCEL earnings summariesRCEL Revenue Breakdown
99.27% Commercial sales
0.67% Services for emergency preparedness
0.07% Deferred commercial revenue
RCEL Stock 12 Month Forecast
Average Price Target
$7.00
▲(75.44% Upside)
Technical Analysis
Ownership Overview
1.37% Insiders
8.66% Mutual Funds
0.29% Other Institutional Investors
82.78% Public Companies and
Individual Investors